Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of... Breast Cancer Res Treat (2018) 168:249–258 https://doi.org/10.1007/s10549-017-4514-z BRIEF REPORT Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer 1,2 3 4 5 • • • • Andrew Dodson David Okonji Laura Assersohn Anne Rigg 6 3 3 3 1,2 • • • • Amna Sheri Nick Turner Ian Smith Marina Parton Mitch Dowsett Received: 9 August 2017 / Accepted: 13 September 2017 / Published online: 11 November 2017 The Author(s) 2017. This article is an open access publication Abstract between RS%-derived categorical risk assignments and Purpose Oncotype DX, a gene expression assay widely treatment recommendation was evaluated. employed to aid decision making on adjuvant chemother- Results Data on 171 tests (168 patients) were available. apy use in patients with primary oestrogen receptor-posi- Median DR risk by RS% was 11% (range 3–34%), by tive (ER?) breast cancer, produces a recurrence score (RS) RSPC it was 15% (range 4–63%). Correlation between related to distant disease recurrence (DR) risk (RS%). In RS% and RSPC was 0.702 (p\ 0.001). RS% classified node-negative patients, RS can be integrated with clinico- 57.3% of cases as low-, 32.2% intermediate- and 10.5% pathological parameters to derive RS-pathology-clinical high-risk http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer

Loading next page...
 
/lp/springer_journal/discordance-between-oncotype-dx-recurrence-score-and-rspc-for-QS402v2D0H
Publisher
Springer US
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4514-z
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2018) 168:249–258 https://doi.org/10.1007/s10549-017-4514-z BRIEF REPORT Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer 1,2 3 4 5 • • • • Andrew Dodson David Okonji Laura Assersohn Anne Rigg 6 3 3 3 1,2 • • • • Amna Sheri Nick Turner Ian Smith Marina Parton Mitch Dowsett Received: 9 August 2017 / Accepted: 13 September 2017 / Published online: 11 November 2017 The Author(s) 2017. This article is an open access publication Abstract between RS%-derived categorical risk assignments and Purpose Oncotype DX, a gene expression assay widely treatment recommendation was evaluated. employed to aid decision making on adjuvant chemother- Results Data on 171 tests (168 patients) were available. apy use in patients with primary oestrogen receptor-posi- Median DR risk by RS% was 11% (range 3–34%), by tive (ER?) breast cancer, produces a recurrence score (RS) RSPC it was 15% (range 4–63%). Correlation between related to distant disease recurrence (DR) risk (RS%). In RS% and RSPC was 0.702 (p\ 0.001). RS% classified node-negative patients, RS can be integrated with clinico- 57.3% of cases as low-, 32.2% intermediate- and 10.5% pathological parameters to derive RS-pathology-clinical high-risk

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Nov 11, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off